ArticleWorld journal of surgical oncology2026
RGS19 drives tumor progression and immunosuppression in clear cell renal cell carcinoma by modulating CAMs and EMT.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) is characterized by poor prognosis and limited treatment options.This study aims to characterize the clinical significance, biological functions, and underlying mechanisms of RGS19 in clear cell renal cell carcinoma (ccRCC) and preliminarily analyze its association with the tumor immune microenvironment.
methodsThe expression pattern of RGS19 was analyzed using TCGA datasets, GEO databases, and clinical specimens. Its biological functions were verified through in vitro assays and in vivo experimental models. Correlations between RGS19 and cell adhesion molecules (CAMs), epithelial-mesenchymal transition (EMT)-related genes, and signaling pathways were analyzed. Immune infiltration analysis was also performed to explore the association between RGS19 expression and tumor immune microenvironment.
resultsRGS19 was markedly elevated in ccRCC tissues and cell lines compared with normal control groups. Its elevated expression correlated with advanced TNM stage, higher histologic grade, and poorer overall, progression-free, and disease-specific survival, establishing it as an independent prognostic factor. Furthermore, functional assays confirmed that RGS19 depletion curbed ccRCC cell proliferation, migration, and invasion in vitro, and attenuated tumor growth in xenograft models. RGS19 overexpression exerted the opposite effects. RGS19 was positively correlated with CAMs and EMT-related genes, and enriched in cell adhesion and EMT signaling pathways. Furthermore, expression of RGS19 was associated with increased infiltration of immunosuppressive cell populations and diminished infiltration of Th17 cell subsets.
conclusionRGS19 promotes ccRCC progression through CAM-mediated adhesion, EMT, and immunosuppression, suggesting its clinical utility as a prognostic marker and a promising target for therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.